Your search matched 7 results
Dramatic changes in U.S. healthcare over the last few years have forced a rethinking of the partnerships pharmaceutical companies form with groups representing patients and families.
Since the fall of 2015, and against a backdrop of harsh media attention to pharmaceutical pricing, patient advocacy groups that form partnerships with pharma companies have received negative coverage in The New York Times, USA Today and other publications.
PATIENT PARTNERS IN ONCOLOGY | Perspectives
Noticing important shifts in the rules of engagement between industry and patient advocates, Syneos Health Public Relations Group conducted in-depth interviews with dozens of patient organizations in early 2015.
Our PR Group is just back from Strengthening Patient Advocacy Relations Conference where Meg Alexander, Head, Reputation & Risk Management & Chris Iafolla, Head, Digital & Social Strategy, presented “Worlds Colliding: When Patient Activism Meets Pharma’s Digital Channels".
SHARING THE MISSION TO CONQUER RARE DISEASES | Perspectives
At an ever-quickening pace, biopharmaceutical companies and patient advocacy groups are banding together to hasten development of new drugs for rare diseases.
Artificial Intelligence | Perspectives
An AI wave is poised to transform healthcare with examples ranging from supercomputers identifying hard-to-diagnose cancers; robots assisting surgeons with complex procedures; and chatbot therapists supporting patients with cognitive behavioural therapy.
The pharmaceutical industry recognizes that consumer behavior is a key to both better individual health outcomes and greater business success, and has created a wide range of programs to engage and support patients who are taking prescribed medication.